newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of